Urokinase for cerebral hemorrhage

(1) urokinase is expected to be an ideal drug for minimally invasive surgery combined with fibrinolysis to remove cerebral hemorrhage

Surgical removal of intracerebral hematoma is the main method for the treatment of severe intracerebral hemorrhage. At present, tPA is commonly used as a fibrinolytic drug for blood clots in foreign countries. It is not only expensive, but also recently reported that tPA may cause delayed brain edema and nerve damage. Chen qianwei et al. first compared the efficacy and side effects of urokinase and tPA in the animal model of intracerebral hemorrhage. They found that both drugs can effectively reduce the volume of cerebellar hematoma, and urokinase may be more advantageous in cerebral edema and neuroprotection, suggesting that urokinase is expected to be one of the ideal drugs for fibrinolytic treatment of patients with cerebral hemorrhage in the future.

Urokinase has a special effect in the treatment of cerebral hemorrhage

The neurosurgery team of the southwest hospital of the third military medical university found that urokinase has a special role in the treatment of cerebral hemorrhage. The research group carried out specific studies and animal experiments for more than two years, and found that the use of urokinase plasminogen activator (uPA) in the minimally invasive surgery for the removal of cerebral hemorrhage has the effect of reducing the volume of cerebral hematoma and can better protect the brain nerve tissue. This means that the research of fibrinolytic drugs for minimally invasive treatment of cerebral hemorrhage has made a breakthrough in stages, and the safety and effectiveness of surgical treatment for cerebral hemorrhage will be further improved in the future.